Stability of oral pancreatin powders.
In-vitro study which duplicated the conditions to which the orally administered pancreatin is exposed in the human stomach showed that the oral administration of pancreatin in uncoated powder form could result in a substantial loss of enzymic activity. Therefore, it may not be an efficacious replacement therapy in pancreatic disorders where pancreatin secretion is reduced.
D000681:Amylases; D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D008049:Lipase; D010194:Pancreatin / Q000032:analysis* / Q000378:metabolism; D010447:Peptide Hydrolases; D011208:Powders; D013696:Temperature
D011208:Powders; D010194:Pancreatin; D008049:Lipase; D000681:Amylases; D010447:Peptide Hydrolases